

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Plastic box of 2 x 1ml,
10 x 1 ml, 20 x 1 ml, 50 x 1 ml, 100 x 1 ml}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Merilym 3 suspension for injection.

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Per 1 d. (1 ml):

Inactivated *Borrelia burgdorferi sensu lato*:

<i>Borrelia garinii</i>	RP ≥ 1
<i>Borrelia afzelii</i>	RP ≥ 1
<i>Borrelia burgdorferi</i>	RP ≥ 1

3. PACKAGE SIZE

2 x 1 ml
10 x 1 ml
20 x 1 ml
50 x 1 ml
100 x 1 ml

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Protect from light.

Store and transport refrigerated.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Animal Health UK Limited.

14. MARKETING AUTHORISATION NUMBERS

Vm 08327/5035

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet.

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {Glass vial}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Merilym 3



2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

1 d. (1 ml)

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

5. ROUTE(S) OF ADMINISTRATION

6. THE WORDS “FOR ANIMAL TREATMENT ONLY”

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Merilym 3, suspension for injection for dogs

2. COMPOSITION

Each 1 ml dose contains:

Active substances:

Borrelia burgdorferi sensu lato:

Borrelia garinii, strain BR14, inactivated *RP* ≥ 1*

Borrelia afzelii, strain BR33, inactivated *RP* ≥ 1*

Borrelia burgdorferi, strain DSM 4681, inactivated *RP* ≥ 1*

*RP = Relative potency (ELISA test) compared with the reference serum obtained after vaccination of mice with a vaccine batch that has successfully passed the challenge test in the target species.

Adjuvant:

Aluminium (as hydroxide) 2 mg

Excipients:

Formaldehyde max. 0.5 mg

Pinkish up to white fluid containing white sediment that disperses easily when the content is shaken.

3. TARGET SPECIES

Dogs.

4. INDICATIONS FOR USE

For active immunization of dogs from 12 weeks of age, to induce an anti-OspA response against *Borrelia* spp. (*B. burgdorferi*, *B. garinii* and *B. afzelii*).

Reduction of *Borrelia* transmission was only investigated under laboratory conditions, following a challenge with field ticks (collected from a region known to be affected by *Borrelia*). Under these conditions, it was shown that no *Borrelia* could be isolated from the skin of vaccinated dogs, while *Borrelia* were isolated from the skin of non vaccinated dogs.

Reduction of transmission of *Borrelia* from the tick to the host has not been quantified, and no correlation has been established between a specific level of antibodies and reduction of *Borrelia* transmission. The efficacy of the vaccine against an infection that leads to the development of clinical disease has not been studied.

Onset of immunity: 1 month after primary vaccination.

Duration of immunity: 1 year after primary vaccination.

5. CONTRAINDICATIONS

Do not use in case of general febrile illness.

Do not use in sick animals that have intercurrent disease, heavy parasitic infestation and/or are in poor general condition.

Do not use in case of suspected or confirmed Lyme borreliosis.

Do not use in cases of hypersensitivity to the active substances, to the adjuvant or to any of the excipients.

6. SPECIAL WARNINGS

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

No information is available on the use of the vaccine in seropositive animals including those with maternally derived antibodies.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No other adverse events than those described in section 7 were observed after administration of a double dose.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. ADVERSE EVENTS

Dogs:

Rare (1 to 10 animals / 10 000 animals treated):

Injection site swelling.¹ Anorexia (loss of appetite), lethargy.

Very rare (<1 animal / 10 000 animals treated, including isolated reports):

Injection site swelling.² Elevated temperature.³ Hypersensitivity reaction.⁴

¹ Up to 7 cm in diameter, for up to 5 days.

² Up to 15 cm in diameter.

³ Transient, up to 1.5°C.

⁴ Which may require appropriate symptomatic treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Dose:

1 ml from 12 weeks of age.

Method of administration:

Subcutaneous use.

Primary vaccination:

Administer two doses separated by an interval of 3 weeks.

Revaccination:

Annual revaccination with a single dose is recommended to maintain immunity although this schedule has not been investigated.

Vaccination should be carried out prior to periods of increased tick activity, allowing sufficient time for the immune response to vaccination to develop fully (see section 4) prior to expected tick exposure.

9. ADVICE ON CORRECT ADMINISTRATION

Shake the vial well before use.

10. WITHDRAWAL PERIODS

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Protect from light.

Store and transport refrigerated (2 °C – 8 °C).

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: use immediately.

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 08327/5035

Pack sizes:

Plastic box with 10 wells containing:

10 vials of 1 ml of the vaccine
2 vials of 1 ml of the vaccine

Plastic box with 20 wells:
20 vials of 1 ml of the vaccine

Plastic box with 100 wells:
100 vials of 1 ml of the vaccine
50 vials of 1 ml of the vaccine

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder and contact details to report suspected adverse reactions:

Boehringer Ingelheim Animal Health UK Limited
Ellesfield Avenue
Bracknell
Berkshire
RG12 8YS

Manufacturer responsible for batch release:

Bioveta a.s
Komenského 212/12
683 23 Ivanovice na Hané
Czechia

Local representatives and contact details to report suspected adverse reactions:

United Kingdom (Great Britain):

Boehringer Ingelheim Animal Health UK Ltd., United Kingdom
Tel: + 44 1344 746957

17. OTHER INFORMATION

The vaccine induces specific anti-OspA antibodies against *Borrelia burgdorferi sensu lato*. Scientific literature are available which indicate that during a tick blood feeding, vaccine-induced antibodies present in the blood are ingested by the tick and are expected to bind to OspA proteins expressed by the bacteria in the tick gut; this is expected to reduce their migration to the salivary glands and transmission to the host.

POM-V Veterinary medical product subject to prescription.

For animal treatment only.

Gavin Hall
Approved: 23 January 2025